Skip to main content
Study looks at newer antipsychotic among Alzheimer's patients

A drugmaker-funded study in The Lancet Neurology showed a newer antipsychotic, pimavanserin, may reduce psychosis symptoms in Alzheimer's disease patients without the side effects linked to other antipsychotics. Pimavanserin blocks the THT2A nerve receptor in the brain.

Full Story: